Scarica l'app Stockscreener
56.90
11.14%
-7.13
Dopo l'orario di chiusura:
55.36
-1.54
-2.71%
Precedente Chiudi:
$64.03
Aprire:
$64
Volume 24 ore:
100.77K
Relative Volume:
2.43
Capitalizzazione di mercato:
$1.84B
Reddito:
-
Utile/perdita netta:
$-32.61M
Rapporto P/E:
-48.46
EPS:
-1.1742
Flusso di cassa netto:
-
1 W Prestazione:
-14.69%
1M Prestazione:
-4.85%
6M Prestazione:
+11.59%
1 anno Prestazione:
+45.93%
Intervallo 1D:
$55.00
$64.12
Intervallo di 1 settimana:
$55.00
$66.76
Portata 52W:
$31.00
$86.53
Belite Bio Inc Adr Stock (BLTE) Company Profile
Nome
Belite Bio Inc Adr
Settore
Industria
Telefono
-
Indirizzo
-
Confronta BLTE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BLTE
Belite Bio Inc Adr
|
56.90 | 1.84B | 0 | -32.61M | 0 | -1.1742 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Belite Bio Inc Adr Stock (BLTE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-12-14 | Iniziato | Maxim Group | Buy |
| 2023-07-28 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-07-26 | Iniziato | SVB Securities | Outperform |
| 2022-08-01 | Iniziato | H.C. Wainwright | Buy |
| 2022-07-01 | Iniziato | The Benchmark Company | Buy |
Belite Bio Inc Adr Borsa (BLTE) Ultime notizie
Belite Bio, Inc. Appoints New Auditor - TipRanks
Benchmark Reiterates Buy Rating for Belite Bio (NASDAQ:BLTE) - Defense World
Belite Bio stock target raised to $80 at Benchmark By Investing.com - Investing.com South Africa
Belite Bio price target raised to $80 from $79 at Benchmark - TipRanks
Belite Bio stock target raised to $80 at Benchmark - Investing.com
Belite Bio, Inc. ADR: Promising Clinical Progress and Strong Financial Position Drive Buy Rating - TipRanks
Cantor Fitzgerald Forecasts Weaker Earnings for Belite Bio - Defense World
Belite Bio, Inc (NASDAQ:BLTE) Short Interest Up 17.1% in February - Defense World
HC Wainwright Has Pessimistic View of Belite Bio Q1 Earnings - Defense World
Belite Bio (NASDAQ:BLTE) Receives Buy Rating from HC Wainwright - Defense World
Belite Bio’s (BLTE) “Overweight” Rating Reaffirmed at Cantor Fitzgerald - Defense World
Belite Bio’s Earnings Call: Cautious Optimism Amid Progress - TipRanks
Belite Bio Announces 2025 Annual Shareholder Meeting - TipRanks
Belite Bio stock holds $100 target post-results - Investing.com India
Positive Buy Rating for Belite Bio, Inc. Driven by Promising Phase 3 DRAGON Trial Results and Regulatory Prospects - TipRanks
Belite Bio (NASDAQ:BLTE) Shares Gap Down After Earnings Miss - Defense World
Belite Bio Advances in Retinal Disease Trials and Financial Position - TipRanks
Earnings call transcript: Belite Bio ADR Q4 2024 sees steady R&D progress - Investing.com Australia
Belite Bio reports Q4 EPS (32c), consensus (31c) - TipRanks
Belite Bio Reports 2024 Financial Results and Clinical Progress - TipRanks
Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website - Markets Insider
Belite Bio Releases 2024 Annual Report on Website - TipRanks
Belite Bio Reports Positive Interim Analysis Results for Phase 3 DRAGON Trial and Financial Update for Q4 2024 - Nasdaq
Public market insider buying at Savaria (SIS) - The Globe and Mail
Belite Bio's $145M War Chest Powers Critical Phase 3 Eye Disease Trial - StockTitan
Belite Bio (NASDAQ:BLTE) Trading Down 1.6% – Time to Sell? - Defense World
Dry AMD Market Expected to rise, 2034 | Alkeus Pharmaceuticals, Belite Bio, Aviceda Therapeutics, Johnson & Johnson Innovative Medicine, Allegro Ophthalmics, Lineage Cell Therapeutics - The Globe and Mail
Belite Bio to Host Webcast on March 17, 2025, to Discuss Fourth Quarter and Full Year 2024 ... - The Bakersfield Californian
Biotech Pioneer Belite Bio Unveils Q4 and 2024 Performance: Key Retinal Disease Updates Coming March 17 - StockTitan
Is Meta Platforms Stock a Buy, Sell, or Hold Ahead of Llama 4 Launch? - The Globe and Mail
Parkland Reports Fourth Quarter and Year-End 2024 Results; Initiates Review of Strategic Alternatives - The Globe and Mail
Darwin CX Expands Internationally, Aiming to Tackle Global Publishing Challenges with Locally Tailored Solutions - The Globe and Mail
Can Belite Bio's Retinal Disease Treatments Impress Investors at Upcoming Leerink Conference? - StockTitan
2 Large-Cap Stocks with Exciting Potential and 1 to Avoid - The Globe and Mail
Belite Bio (NASDAQ:BLTE) Shares Gap UpShould You Buy? - MarketBeat
Promising Phase 3 Results for Belite Bio’s Tinlarebant in Stargardt Disease Boost Buy Rating - TipRanks
Belite Bio’s Phase 3 Trial for Stargardt Disease Drug Advances - TipRanks
Belite Bio Announces Interim Analysis Results from the - GlobeNewswire
Can Belite Bio's Tinlarebant Become First Treatment for Stargardt Disease? Phase 3 Data Shows Promise - StockTitan
Belite Bio (NASDAQ:BLTE) Sees Unusually-High Trading VolumeTime to Buy? - MarketBeat
Belite Bio (NASDAQ:BLTE) Sees Unusually-High Trading Volume – Still a Buy? - The AM Reporter
Belite Bio, Inc (NASDAQ:BLTE) Short Interest Down 9.2% in January - MarketBeat
Belite Bio (NASDAQ:BLTE) Stock Price Up 7.8%Should You Buy? - MarketBeat
Belite Bio (NASDAQ:BLTE) Shares Down 4.7%Time to Sell? - MarketBeat
Advisors Preferred LLC Purchases New Shares in Belite Bio, Inc (NASDAQ:BLTE) - Armenian Reporter
Belite Bio Announces $15 Million Direct Offering to Enhance Financial Position - TipRanks
BLTEBelite Bio, Inc Latest Stock News & Market Updates - StockTitan
Sangoma Announces Second Quarter Fiscal 2025 Results - The Globe and Mail
Why Oklo Stock Jumped 96% in January - The Globe and Mail
Belite Bio Inc Adr Azioni (BLTE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.01%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):